The assessment of Crohn's disease activity through endoscopy is a cornerstone of both clinical management and research. In The Lancet Gastroenterology & Hepatology, Christopher Ma and colleagues ...

SEOUL, June 9 (Yonhap) -- South Korean chip giant SK hynix Inc. ranked first in operating profit among 1,000 major listed ...

Lee Ga-young showed his senior's true face to the spirited 19-year-old rookie.Lee Ga-young lifted the trophy after a neck-and ...

Going forward, Celltrion is expected to continue its current strategy, aiming to have a total of 23 biosimilar products by 2030, covering therapeutic areas such as immunology and oncology. We sell ...

In the last month, the FDA has granted interchangeability status to additional adalimumab biosimilars.  Biosimilars with an ...

The FDA has expanded the interchangeable designation for Yuflyma (adalimumab-aaty), a biosimilar to Humira, to include all presentations.

With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help ...

Since the European Medicines Agency (EMA) approval of omalizumab in 2005 as the first ever biologic for severe asthma, the ...

South Korean biopharmaceutical firm Celltrion announced Wednesday that the market share of Remsima SC, the subcutaneous ...

South Korea’s largest biosimilar maker Celltrion Inc. said on Friday that it has scrapped a plan to merge with Celltrion Pharm Inc., an R&D and local distribution affiliate, in the face of opposition ...

South Korea’s leading biosimilar drug developer Celltrion Inc. on Sunday unveiled an anticancer medicine to expand new pipelines and accelerate its transformation into an original drug developer.

Shares finished lower Tuesday as investors moved to lock in profits from recent gains amid lingering concerns about the ...